SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (583)4/8/1999 5:54:00 PM
From: scaram(o)ucheRead Replies (1) | Respond to of 4974
 
"The most frequently reported adverse events were tiredness and drowsiness"

Too bad. And I had such high hopes for this candidate.

- g -

biz.yahoo.com

I'll nominate completion of the Phase Ib multiple dose,
dose-escalating study for NBI-34060, a GABA(A) receptor subtype agonist.

Also, GENXY delivered to Synthelabo a third gene in its prostate program, triggering a milestone payment. More progress from positional cloning.